Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Health experts are raising concerns for women using popular weight loss medications, particularly GLP-1s like Wegovy, ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

Participants who are taking GLP-1 medications and have taken them for at least 3 months are needed for a study on eating behavior.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...